Want to see FLNA full AI Analyst Report?
Filana Therapeutics (FLNA) Risk Analysis
Risk Overview Q3, 2024
Risk Change Over Time
- Innovation / R&D - Risk 1The validity of aspects of the Company's Phase 2b Study has been called into question.
The Company's Phase 2b Study was designed as a 28-day, approximately 60-patient, randomized, double-blind, placebo-controlled, multiple dose study. A primary objective of the Phase 2b Study was to measure changes in levels of cerebral spinal fluid ("CSF") biomarkers in study participants from baseline value to Day 28. CSF biomarker assays and related bioanalysis for the Phase 2b Study (the "CUNY Bioanalysis") were conducted by the laboratory at CUNY of Dr. Hoau-Yan Wang, formerly a paid scientific collaborator, consultant and advisor to Cassava. Based on the CUNY Bioanalysis, Cassava reported statistically significant improvements in CSF biomarkers in treatment groups as compared to the placebo group for the Phase 2b Study. On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Wang alleging that he caused Cassava to submit grant applications to NIH that contained false and fraudulent representations about his research. Among other things, the indictment alleges that Dr. Wang made materially false, fraudulent, and misleading statements to NIH regarding the mechanism by which simufilam was designed to treat Alzheimer's disease and the improvement of certain Alzheimer's disease indicators in patients treated with simufilam, and that Dr. Wang manipulated or otherwise fabricated research results, including Western Blot images that he prepared. As part of the Internal Investigation being conducted by the Ad Hoc Investigation Committee of the Company's Board of Directors, the Committee has evaluated information contained in the DOJ indictment of Dr. Wang as well as information from the Company's discussions with the SEC. To date, the Internal Investigation has determined that certain statistical information contained in an attachment to an email sent by a former senior employee of Cassava to Dr. Wang before the CUNY Bioanalysis of CSF biomarkers was conducted could have been used to unblind him as to some number of Phase 2b Study participants. Unblinded information, if accessed in connection with bioanalysis, could be improperly utilized to manipulate underlying samples or data to skew reported results. The Internal Investigation has not, to date, determined, and may never be able to determine with any reasonable degree of certainty, whether Dr. Wang unblinded himself as to some number of Phase 2b Study participants. Nevertheless, the fact that Dr. Wang possessed information that could have been used to so unblind himself, together with the allegations in the DOJ indictment, undermine the blinded study design and create substantial uncertainty about the validity of the CUNY Bioanalysis of CSF biomarkers. In addition, another objective of the Phase 2b Study was to measure changes in cognitive outcome measures using the Cambridge Neuropsychological Test Automated Battery, or CANTAB, over the 28-day study period. In connection with our settlement with the SEC, the SEC's complaint alleged, among other things, that disclosures relating to the Phase 2b Study's cognition results (the "Cognition Disclosures"), which reported results from a post hoc sensitivity analysis, were inadequate and misleading. Accordingly, in light of the foregoing uncertainties and allegations, you should not rely on the CUNY Bioanalysis of CSF biomarkers reported by the Company in connection with the Phase 2b Study or the Cognition Disclosures from the Phase 2b Study. There can be no assurance that such uncertainties and allegations will not adversely impact the FDA's review of an NDA with respect to simufilam following completion of our Phase 3 clinical studies or cause the FDA to request additional information regarding simufilam.
Risk Highlights Q3, 2024
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 52
- Share Price & Shareholder Rights - Risk 1Ownership of our corporate headquarters and property leasing are subject to numerous risks and uncertainties.
In 2021, we made an all-cash purchase of an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. Title to this property is held by Austin Innovation Park, LLC, a Texas limited liability company wholly owned by Cassava Sciences. The purchase required a substantial upfront cash investment and may require further commitments of our resources in the future. We have assumed or entered into lessor commitments with independent third parties for portions of our office complex and expect to continue to do so. Commercial property ownership and related leasing activity are subject to many factors that pose substantial financial risks and uncertainties, including tenant default, non-payment of lease obligations, market value fluctuations and natural disasters.
- Share Price & Shareholder Rights - Risk 2We do not know whether a sufficient market will continue to develop for our securities or what the market price of our securities will be, and, as a result, it may be difficult for investors to sell shares of our common stock or outstanding warrants.
The market for our common stock and outstanding warrants may not be sufficiently liquid or may not develop as anticipated, making it difficult for investors to sell their shares or warrants at attractive prices.
- Share Price & Shareholder Rights - Risk 3The market price of our common stock has historically been highly volatile, and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares.
Our common stock has experienced significant price fluctuations, for example ranging from a low of $12.64 to a high of $30.11 over the past 12 months. Such volatility could result in substantial losses for investors and may continue in the future.
- Share Price & Shareholder Rights - Risk 4Hedging arrangements relating to our warrants may affect the value and volatility of our common stock.
Certain warrant holders may engage in hedging transactions that could adversely affect the market price and volatility of our common stock.
- Share Price & Shareholder Rights - Risk 5The trading price for our warrants may bear little or no relationship to traditional valuation methods, or to the market price of our common stock, and therefore the trading price of the warrants may fluctuate significantly.
Due to factors such as traditional valuation not accurately representing the warrants’ value and market conditions, the trading price for our warrants may fluctuate significantly and may not correlate with the market price of our common stock.
- Share Price & Shareholder Rights - Risk 6If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline.
A lack of coverage by securities analysts or negative publicity regarding our business may lead to a decline in the market price of our common stock.
- Share Price & Shareholder Rights - Risk 7Short sellers of our stock may be manipulative and may drive down the market price of our common stock.
Short sellers may engage in manipulative tactics that drive down the market price of our common stock, which could adversely affect investor value.
- Share Price & Shareholder Rights - Risk 8Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control.
Our amended and restated certificate of incorporation and bylaws, along with applicable Delaware law, contain provisions such as a classified board, elimination of cumulative voting, and the ability to issue preferred stock without stockholder approval. These provisions could deter or delay changes in management or a change of control even if such changes might be beneficial to stockholders.
- Share Price & Shareholder Rights - Risk 9Our amended and restated bylaws provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Laws of 1933, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our bylaws designate the federal district courts of the United States as the exclusive forum for certain securities law claims. This exclusive forum provision may limit our stockholders’ ability to bring claims in other judicial forums, potentially disadvantaging stockholders in litigation.
- Share Price & Shareholder Rights - Risk 10We may sell additional equity or debt securities to fund our operations, and have outstanding securities exercisable for our common stock, which may result in dilution to our stockholders and impose restrictions on our business.
To fund our operations, we may need to raise capital through additional equity or debt financings. Such transactions, as well as the exercise of outstanding stock options, warrants, or other convertible securities, could dilute existing stockholders’ ownership interests and may impose restrictions that could adversely affect our business prospects.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.